Chest
Selected ReportsOfloxacin and the Treatment of Pulmonary Disease due to Mycobacterium fortuitum
Section snippets
CASE REPORT
A 58-year-old man, the manager of a restaurant, who had a history of pulmonary tuberculosis and had received therapy with rifampicin, isoniazid, and streptomycin for about two years (1979 to 1981), was admitted to our hospital in May 1984 for persistent productive cough with a slight fever. He received cephalosporin antibiotics for about three weeks, which was associated with little improvement in the chest roentgenogram. After discharge, he was noticed to have excreted organisms of M fortuitum
DISCUSSION
Mycobacterium fortuitum is resistant to almost all antituberculosis agents; therefore, pulmonary disease due to this organism has been difficult to cure. Our experiences with an in vitro susceptibility study and in the treatment of pulmonary tuberculosis with ofloxacin have suggested the efficacy of this agent in the treatment of pulmonary disease due to M fortuitum.1, 2 The disease is rare. Therefore, we have waited for a chance to use this agent in the treatment of infection with M fortuitum.
REFERENCES (4)
In vitro antimycobacterial activity of a new antibacterial substance DL-8280: differentiation between some species of mycobacteria and related organisms by the DL-8280 susceptibility test
Microbiol Immunol
(1983)- et al.
Therapeutic effect of a new antibacterial substance ofloxacin (DL-8280) on pulmonary tuberculosis
Am Rev Respir Dis
(1985)
Cited by (19)
Clinical significance of Mycobacterium fortuitum isolated from respiratory specimens
2008, Respiratory MedicineCitation Excerpt :M. fortuitum lung disease usually occurs in patients with pre-disposing factors, such as malignancy, renal transplantation, chronic reflux disease, achalasia, bronchiectasis, and cystic fibrosis.16–22 The presentation of pulmonary disease includes lung abscesses,23–25 pneumonia,26,27 pleural effusions,28 and solitary pulmonary nodules,29 etc. In the current study, most patients had underlying lung diseases, including prior pulmonary tuberculosis, bronchiectasis, or other mycobacterial lung disease.
Spinal infection by Mycobacterium xenopi in a non-immunosuppressed patient
1992, Tubercle and Lung DiseaseClinical Characteristics and Treatment Outcomes of Mycobacterium fortuitum Pulmonary Disease
2023, Microbiology SpectrumCiprofloxacin
2017, Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh EditionLung abscess due to non-tuberculous, non-Mycobacterium fortuitum in a neonate
2012, Pediatric Pulmonology